entertainment -WSS

entertainment

author：leisure time 2025-09-27 20:43:44 - browse：3392

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — The booming obesity market is attracting another player, as pharma giant Roche said Monday it was acquiring Carmot Therapeutics and the company’s line of weight loss drug candidates for $2.7 billion upfront.

The deal for Carmot, which is based in Berkeley, Calif., includes additional milestone payments of up to $400 million. Carmot is privately held, though it had filed paperwork last month for an initial public offering.

As part of the deal, Roche is gaining three experimental obesity medicines from Carmot, which are in Phase 1 or Phase 2 testing, as well as preclinical programs. While two are injectable treatments, one is being developed as an oral drug. They all target GLP-1 hormone receptors, while two are also designed to work via receptors for another hormone called GIP.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： How the messy conversation about Dolly changed bioethics

WSS

How to bring more disabled researchers into academia

IVF, abortion rights issues kick off Biden’s State of the Union

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Change Healthcare payments predicted restored March 15

The unintended consequences of overturning Roe v. Wade

Wikipedia

entertainment

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Amylyx ALS drug failure raises questions and concerns

How to save PrEP access — and even expand it

Information blocking fines are now fair game in health care

Duchenne breakthrough therapy leaves behind pioneering families

Free Covid tests will again be offered to all U.S. households

DIEP, the 'gold standard' of breast reconstruction, is under threat

Senate bill would ban some hospital facility fees

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

focus

Information blocking fines are now fair game in health care

FDA weighs limits of animal data in assessing artificial wombs

Covid’s new normal has set in amid another rise in cases

NEJM study link tiny plastics in blood vessels to heart problems

What it’s like to watch children die of measles

Change Healthcare cyberattack prompts Medicare loan program

Wikipedia

leisure time

focus

focus